AU2014229217B2 - Pyridin-4-yl derivatives - Google Patents

Pyridin-4-yl derivatives Download PDF

Info

Publication number
AU2014229217B2
AU2014229217B2 AU2014229217A AU2014229217A AU2014229217B2 AU 2014229217 B2 AU2014229217 B2 AU 2014229217B2 AU 2014229217 A AU2014229217 A AU 2014229217A AU 2014229217 A AU2014229217 A AU 2014229217A AU 2014229217 B2 AU2014229217 B2 AU 2014229217B2
Authority
AU
Australia
Prior art keywords
diseases
ethyl
disorders
oxadiazol
hydroxyacetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014229217A
Other languages
English (en)
Other versions
AU2014229217A1 (en
Inventor
Martin Bolli
Cyrille Lescop
Oliver Nayler
Beat Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AU2014229217A1 publication Critical patent/AU2014229217A1/en
Assigned to IDORSIA PHARMACEUTICALS LTD reassignment IDORSIA PHARMACEUTICALS LTD Request for Assignment Assignors: ACTELION PHARMACEUTICALS LTD
Application granted granted Critical
Publication of AU2014229217B2 publication Critical patent/AU2014229217B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2014229217A 2013-03-15 2014-03-14 Pyridin-4-yl derivatives Ceased AU2014229217B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159482.2 2013-03-15
EP13159482 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (2)

Publication Number Publication Date
AU2014229217A1 AU2014229217A1 (en) 2015-11-05
AU2014229217B2 true AU2014229217B2 (en) 2017-12-14

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014229217A Ceased AU2014229217B2 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Country Status (33)

Country Link
US (1) US9617250B2 (enExample)
EP (1) EP2970236B1 (enExample)
JP (1) JP6387361B2 (enExample)
KR (1) KR102212975B1 (enExample)
CN (1) CN105189487B (enExample)
AR (1) AR095523A1 (enExample)
AU (1) AU2014229217B2 (enExample)
BR (1) BR112015023161B1 (enExample)
CA (1) CA2900910C (enExample)
CL (1) CL2015002620A1 (enExample)
CY (1) CY1119619T1 (enExample)
DK (1) DK2970236T3 (enExample)
EA (1) EA029309B1 (enExample)
ES (1) ES2649475T3 (enExample)
HR (1) HRP20171763T1 (enExample)
HU (1) HUE035154T2 (enExample)
IL (1) IL241363B (enExample)
LT (1) LT2970236T (enExample)
MA (1) MA38482B1 (enExample)
MX (1) MX363545B (enExample)
MY (1) MY173573A (enExample)
NO (1) NO2970236T3 (enExample)
NZ (1) NZ713080A (enExample)
PH (1) PH12015502118A1 (enExample)
PL (1) PL2970236T3 (enExample)
PT (1) PT2970236T (enExample)
SA (1) SA515361104B1 (enExample)
SG (1) SG11201507227UA (enExample)
SI (1) SI2970236T1 (enExample)
TW (1) TWI623534B (enExample)
UA (1) UA115357C2 (enExample)
WO (1) WO2014141171A1 (enExample)
ZA (1) ZA201507657B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
MY192358A (en) 2015-05-20 2022-08-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029371A1 (en) * 2006-09-07 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド S1p1/edg1受容体アゴニストとしてのアミノ−ピリジン誘導体
PL2195311T3 (pl) 2007-08-17 2011-08-31 Actelion Pharmaceuticals Ltd Pochodne pirydynowe jako modulatory receptora S1P1/EDG1
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
CA2714614A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
SI2252609T1 (sl) * 2008-03-07 2013-07-31 Actelion Pharmaceuticals Ltd. Derivati piridin-2-ila kot imunomodulacijska sredstva
BRPI0910288A2 (pt) 2008-03-07 2019-09-24 Actelion Pharmaceuticals Ltd composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
HUE025984T2 (hu) * 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
AR075781A1 (es) 2009-03-03 2011-04-27 Merck Serono Sa Derivados de oxadiazol piridina como agonistas del receptor s1p1/edg1 y un metodo para su preparacion.
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
SG191742A1 (en) 2011-01-19 2013-08-30 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029371A1 (en) * 2006-09-07 2008-03-13 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents

Also Published As

Publication number Publication date
WO2014141171A1 (en) 2014-09-18
TWI623534B (zh) 2018-05-11
AU2014229217A1 (en) 2015-11-05
CN105189487B (zh) 2017-12-26
CY1119619T1 (el) 2018-04-04
BR112015023161A2 (pt) 2017-07-18
EP2970236B1 (en) 2017-08-30
JP6387361B2 (ja) 2018-09-05
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
SI2970236T1 (sl) 2017-11-30
CN105189487A (zh) 2015-12-23
EA029309B1 (ru) 2018-03-30
MX363545B (es) 2019-03-27
DK2970236T3 (en) 2017-10-16
CL2015002620A1 (es) 2016-03-18
BR112015023161A8 (pt) 2021-06-22
CA2900910C (en) 2021-03-30
IL241363B (en) 2018-11-29
MY173573A (en) 2020-02-04
KR102212975B1 (ko) 2021-02-05
BR112015023161B1 (pt) 2022-11-16
PL2970236T3 (pl) 2018-01-31
KR20150128947A (ko) 2015-11-18
JP2016512227A (ja) 2016-04-25
PT2970236T (pt) 2017-11-30
MA38482B1 (fr) 2018-11-30
AR095523A1 (es) 2015-10-21
LT2970236T (lt) 2017-11-10
EP2970236A1 (en) 2016-01-20
HUE035154T2 (en) 2018-05-02
PH12015502118A1 (en) 2016-01-25
HK1220454A1 (en) 2017-05-05
SA515361104B1 (ar) 2016-06-28
ZA201507657B (en) 2022-08-31
MX2015012293A (es) 2015-12-16
HRP20171763T1 (hr) 2017-12-29
IL241363A0 (en) 2015-11-30
ES2649475T3 (es) 2018-01-12
NZ713080A (en) 2020-06-26
TW201443044A (zh) 2014-11-16
MA38482A1 (fr) 2017-12-29
NO2970236T3 (enExample) 2018-01-27
US9617250B2 (en) 2017-04-11
SG11201507227UA (en) 2015-10-29
CA2900910A1 (en) 2014-09-18
UA115357C2 (uk) 2017-10-25
EA201500931A1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
CA2900910C (en) Pyridin-4-yl derivatives
CA2767585C (en) Pyridin-4-yl derivatives
CA2661315C (en) Pyridin-3-yl derivatives as immunomodulating agents
EP2069318B1 (en) Phenyl derivatives and their use as immunomodulators
US20110046170A1 (en) Novel pyrimidine-pyridine derivatives
NZ588438A (en) Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
HK1220454B (en) Pyridin-4-yl derivatives
HK1170479B (en) Pyridin-4-yl derivatives as s1p1/edg1 agonists

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IDORSIA PHARMACEUTICALS LTD

Free format text: FORMER APPLICANT(S): ACTELION PHARMACEUTICALS LTD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired